Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

Status unconfirmed · Phase 2

Conditions studied: Open Angle Glaucoma, Ocular Hypertension

In brief

The goal of this clinical trial is to learn about the safety of Travoprost Ophthalmic Topical Cream and how well it works in lowering high intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). A low dose, medium dose and high dose of Travoprost Ophthalmic Topical Cream will be compared to timolol maleate ophthalmic solution, 0.5% and to travoprost ophthalmic solution, 0.004%.

Key facts

Study ID

NCT06152861

Run by

Glaukos Corporation

People needed

250

Starts

2023-11-15

Expected to finish

2024-08-01

Last updated by the study team

2023-12-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female, 18 years of age or older at the Screening Visit;
• Willing and able to provide written informed consent on the IRB/IEC-approved informed consent form;
• Diagnosis of OAG (including pigmentary and pseudoexfoliative) or OHT in both eyes;
• Qualifying IOP in the study eye;
• Best-corrected visual acuity of approximately 20/80 Snellen in each eye

You may not qualify if…

• Sensitivity or allergy to travoprost or timolol;
• Bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease;
• History of or current sinus bradycardia, second- or third-degree atrioventricular block, overt cardiac failure, or cardiogenic shock;
• History of cerebrovascular insufficiency;
• Any form of glaucoma other than open-angle glaucoma
• Advanced visual field loss or cup-to-disc ratio of 0.8 or greater
• Non-qualifying prior surgeries or procedures in either eye

Where it is running

• Glaukos Clinical Study Site — Newport Beach, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.